Actively Recruiting
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Led by Dispatch Biotherapeutics · Updated on 2026-04-27
66
Participants Needed
2
Research Sites
1043 weeks
Total Duration
On this page
Sponsors
D
Dispatch Biotherapeutics
Lead Sponsor
B
Bristol-Myers Squibb
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a Phase 1, multicenter, open-label study of DISP-10, a combination therapy consisting of DV-10 (adenovirus) and idecabtagene vicleucel (ide-cel, BCMA-directed chimeric antigen receptor \[CAR\] T), in adult participants with advanced gastrointestinal (GI) cancers. The study will consist of 2 parts: dose-escalation (Part 1) and dose-expansion (Part 2). Part 1 of the study will evaluate the safety and tolerability of increasing dose levels of DISP-10 to establish the recommended dose for expansion (RDE); Part 2 will evaluate the safety and efficacy of DISP-10 in participants treated at the RDE.
CONDITIONS
Official Title
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed advanced or metastatic esophageal, gastroesophageal junction, gastric adenocarcinoma, or colorectal adenocarcinoma
- Measurable disease by RECIST v1.1 with at least 1 site suitable for biopsy
- ECOG performance status of 0 or 1
- Age 18 years or older at time of informed consent
- Adequate organ function
You will not qualify if you...
- Previous solid organ or hematopoietic cell transplant
- Rapid disease progression within 3 months of prior therapy
- Known history of hepatitis B or HIV infection
- Previous or concurrent malignancy unless cured more than 3 years prior
- Active central nervous system metastases
- Clinically significant pleural or pericardial effusion or peritoneal carcinomatosis
- Currently receiving antiviral treatment
- Severe hypersensitivity to fludarabine or cyclophosphamide
- Prior treatment with oncolytic viruses or T cell derived cellular therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
City of Hope
Duarte, California, United States, 91010
Actively Recruiting
2
Tennessee Oncology
Nashville, Tennessee, United States, 37203
Actively Recruiting
Research Team
D
Dispatch Clinical
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here